Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Oncologic PET Registry Data Confirm FDG-PET has Major Impact on Management of Cancer Patient Care

By MedImaging staff writers
Posted on 21 Apr 2008
A new study analyzed data regarding nearly 23,000 patients contributed to a U.S. More...
oncologic PET registry by more than 1200 facilities in the United States providing positron emission tomography (PET) scans.

Clinicians changed the intended care of more than one in three cancer patients as the result of fluorodeoxyglucose- (FDG)-PET scan findings, according to a study of data from the U.S. National Oncologic PET Registry (NOPR), published online March 24, 2008, in the Journal of Clinical Oncology (JCO).

Sponsored by the Academy of Molecular Imaging (AMI; Los Angeles, CA, USA) and managed by the American College of Radiology (ACR; Philadelphia, PA, USA) and American College of Radiology Imaging Network (ACRIN), the NOPR was designed to collect questionnaire data from referring physicians on intended patient management before and after an FDG-PET scan.

The NOPR-participating PET facility collected from referring physicians both a pre-PET questionnaire (documenting study indication, cancer type and anticipated stage, and planned management if PET were not available) and one of several post-PET questionnaires that assessed the referring physician's planned management in light of the FDG-PET findings.

Analysis of data collected found that FDG-PET is associated with a 36.5% change in the decision of whether or how to treat a patient's cancer. NOPR working group co-chair R. Edward Coleman, M.D., professor of radiology and chief of the division of nuclear medicine at Duke University School of Medicine (Durham, NC, USA) and an AMI founding member, commented, "We were especially surprised by the impact of the PET findings on patients who were originally planned to have a biopsy. The procedure was avoided in approximately three-quarters of these patients.”

FDG-PET, is an imaging modality that images the function of cells to show differences between healthy tissue and diseased tissue. It uses a small amount of a radioactive chemical, which is combined with glucose. This combination is called FDG, and is used to evaluate various neurologic and cardiac disorders, as well as for diagnosing, staging, and monitoring the treatment of many different cancers.


Related Links:
National Oncologic PET Registry
Virginia Commonwealth University
American College of Radiology Imaging Network

Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Post-Processing Imaging System
DynaCAD Prostate
Mobile X-Ray System
K4W
Ultrasound Table
Women’s Ultrasound EA Table
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Imaging IT

view channel
Image: QT Imaging’s latest breast imaging software adds enhanced reflection images by combining speed-of-sound and reflection data (photo courtesy of QT Imaging)

Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases

Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.